Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 5,133,106 shares, a drop of 17.8% from the January 15th total of 6,246,481 shares. Based on an average daily volume of 1,070,048 shares, the days-to-cover ratio is presently 4.8 days. Currently, 9.0% of the shares of the stock are sold short. Currently, 9.0% of the shares of the stock are sold short. Based on an average daily volume of 1,070,048 shares, the days-to-cover ratio is presently 4.8 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. JPMorgan Chase & Co. increased their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Guggenheim lifted their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $104.45.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. State of Wyoming bought a new position in Structure Therapeutics in the 2nd quarter worth about $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the period. CWM LLC grew its stake in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. Assetmark Inc. increased its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded down $2.07 during mid-day trading on Monday, hitting $69.97. The company’s stock had a trading volume of 1,252,099 shares, compared to its average volume of 977,623. The company has a 50 day moving average of $75.01 and a 200-day moving average of $43.40. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The stock has a market cap of $4.25 billion, a PE ratio of -57.35 and a beta of -2.07.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.